Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 05, 2023 16:05 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics Provides Business Update and Outlines 2023 Company Priorities

- CX-2029 (CD71 conditionally activated ADC) continued to demonstrate encouraging anti-cancer activity in squamous tumors in the now completed Phase 2 Cohort Expansion Study. AbbVie and CytomX to...
January 05, 2023 16:05 ET | Source: CytomX Therapeutics Inc.

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Collaboration will combine Moderna’s mRNA technology with CytomX’s Probody® Platform to generate and develop therapeutics for oncology and non-oncology conditions CytomX to receive $35 million...
December 22, 2022 17:00 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics to Outline 2023 Company Priorities and Provide Pipeline Update on January 5, 2023

SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...
December 20, 2022 17:00 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...
December 07, 2022 16:30 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics to Present Phase 2 Data for Praluzatamab Ravtansine (CX-2009) in Patients with Advanced Breast Cancer at the San Antonio Breast Cancer Symposium

SOUTH SAN FRANCISCO, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...
November 17, 2022 07:00 ET | Source: CytomX Therapeutics Inc.

CytomX and Regeneron Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

- Collaboration will enable the development of investigational next-generation bispecific immunotherapies using CytomX’s Probody® and Regeneron's Veloci-Bi® platforms - - CytomX to receive $30...
November 08, 2022 16:10 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

- Advancing wholly owned, next-generation conditionally activated therapeuticsCX-2051 (EpCAM-directed ADC) and CX-801 (Interferon alpha-2b), with INDs anticipated in 2023 - - CX-904, Company’s...
November 07, 2022 16:15 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Interferon Alpha-2b (CX-801) at the SITC 2022 Annual Meeting

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...
November 02, 2022 16:15 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics to Present at Upcoming November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...
November 01, 2022 08:00 ET | Source: CytomX Therapeutics Inc.

CytomX Therapeutics to Report Third Quarter 2022 Financial Results on November 8, 2022

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that...